STOCK TITAN

Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) announced its participation in the H.C. Wainwright 6th Annual NASH Virtual Investor Conference on October 17, 2022, at 12:00 p.m. E.T. The webcast will be accessible via the company's investor relations website, with an archived replay available afterward.

Akero is focused on developing innovative treatments for serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH), which currently has no approved therapies. Their lead candidate, efruxifermin (EFX), shows promise as a potential best-in-class option for NASH treatment.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the H.C. Wainwright 6th Annual NASH Virtual Investor Conference on Monday, October 17, 2022, at 12:00 p.m. E.T.

A webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). EFX is also being evaluated in an expansion cohort of the SYMMETRY study, comparing the safety and tolerability of EFX to placebo when added to an existing GLP-1 receptor agonist in patients with pre-cirrhotic NASH (F1-F3 fibrosis) and Type 2 diabetes.

Investor Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com

Media Contact:
650.487.6488
media@akerotx.com


FAQ

When is Akero Therapeutics presenting at the NASH Investor Conference?

Akero Therapeutics will present at the H.C. Wainwright 6th Annual NASH Virtual Investor Conference on October 17, 2022, at 12:00 p.m. E.T.

How can I watch the Akero Therapeutics presentation?

The presentation can be viewed through the investor relations section of Akero Therapeutics' website, and an archived replay will be available afterward.

What is the focus of Akero Therapeutics?

Akero Therapeutics focuses on developing treatments for serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH), which lacks approved therapies.

What is efruxifermin (EFX) and its significance?

Efruxifermin (EFX) is Akero's lead product candidate designed to treat NASH. It aims to be a potentially best-in-class medicine, offering convenient once-weekly subcutaneous dosing.

What clinical trials is Akero Therapeutics conducting?

Akero is conducting two Phase 2b clinical trials: the HARMONY study for pre-cirrhotic NASH and the SYMMETRY study for cirrhotic NASH.

Akero Therapeutics, Inc.

NASDAQ:AKRO

AKRO Rankings

AKRO Latest News

AKRO Stock Data

1.98B
59.15M
5.33%
105.4%
5.19%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO